SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A bearish BMF report questioning SELLASs REGAL trial design, statistical power, historical controls and valuation triggered the selloff and drove attention to SLS. Traders are divided between dismissing the report as a short-side thesis and worrying that the delayed 80th event could signal unfavorable results, while bullish participants point to prolonged patient survival and the pending readout.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Attention is centered on Uniswaps UNIfication governance proposal to activate protocol fee capture and introduce treasury and future fee-funded UNI burns, which traders view as a potential token-value and supply catalyst. The community is broadly bullish, though some note that approval and the full impact of the mechanism remain uncertain.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Quarterly results and forward guidance are driving attention, as traders debate whether improving high-power AI demand can offset continued losses, modest revenue and the lack of signed hyperscaler contracts. The broader bullish thesis centers on Navitas GaN/SiC power solutions for AI data centers, while bears remain focused on valuation, dilution and patent litigation risks.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDashs latest quarterly results and outlook are driving attention, with traders citing strong revenue and order growth, adjusted EBITDA above guidance, healthy DashPass adoption, and improving margins. Bulls view the performance as support for continued expansion into grocery, retail, and logistics, while skeptics argue the rally has stretched valuation and could face a post-earnings pullback.

Tema ETF Trust - Tema Space Innovators ETF

Tema Space Innovators ETF

SpaceXs IPO-related selloff and expected lockup releases are driving attention, with traders attributing NASAs weakness and the broader space-sector decline to its sizable SpaceX exposure, alongside reported ETF outflows and pro-rata selling. The community is split between frustration with managements allocations and bearish near-term momentum, and long-term holders who view the pullback as an opportunity to accumulate diversified space exposure.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is drawing attention after Merck and Modernas positive personalized cancer-vaccine trial results were viewed as validating its planned Personalis acquisition and precision-oncology strategy. The resulting rally has prompted profit-taking and a sharp pullback, with traders divided between bullish short-squeeze and long-term AI-healthcare views and bearish concerns over valuation, insider selling, and deal risk.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

A broad rebound in SaaS and enterprise software, alongside easing fears that AI will displace Adobes creative products, is driving attention toward Adobe ahead of earnings. Traders remain divided between viewing the move as a durable AI-enabled recovery and seeing it as an overextended, technically vulnerable rally with renewed downside risk.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

Speculative meme-coin buying is driving attention, with traders highlighting perceived relative strength while Bitcoin and Ethereum weaken and promoting 4CHANs large token supply, locked liquidity, and community-driven branding. Bullish holders frame it as an early, high-upside Bitcoin of memecoins, while skeptics warn that the move resembles a pump-and-dump and question its tokenomics and liquidity claims.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermis first anchor-customer agreement with TensorWave and a strategic Hillcore power alliance have focused attention on Project Matadors AI data-center buildout and expanded power capacity. Traders remain divided: bulls view the deals and new CEO as commercial validation, while skeptics cite the pending guarantor and financing, pre-revenue status, execution risk, and potential dilutionespecially after the stock declined despite the announcements.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Unusual volatility, heavy options activity, and elevated short interest are driving speculation that short covering or call buying is behind Sareptas moves, though some traders attribute the strength to broader biotech momentum and Capricors DMD setback. No confirmed Sarepta-specific announcement dominates the discussion; attention remains focused on upcoming DM1/FSHD and sirolimus-related data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NTHI Heads into Wednesday with a Rare Biotech Convergence: Brain-Cancer Data, Tight Float, and Analyst Targets

DENVER, Colo. ( 247marketnews.com ) — NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock tr...

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update PR Newswire SHELTON, Conn., Aug. 11, 2026 Initiated activities to resume enrollment in a limited number...

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 PR Newswire SHELTON, Conn., Aug. 4, 2026 Company to hold a conference call at 8AM ET on August 11, 2026 to review...

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical...

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 PR...

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why

Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award PR Newswire...

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update PR...

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Intensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know

This account has been verified as an official INTS representative.

Verified Account

Intensity Therapeutics

Reported GAAP EPS of -$1.11 up 66.96% YoY

Intensity Therapeutics reported an increased net loss and higher research and development expenses, while the company faces significant risks regarding future funding requirements and potential delisting from the Nasdaq exchange.

Intensity Therapeutics resumed enrollment for its Phase 3 INVINCIBLE-3 study, while preliminary INVINCIBLE-4 data demonstrated a higher pathological complete response rate and reduced grade 3 adverse events for the company.

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

Intensity Therapeutics Inc

Why Did INTS Stock Plummet 25% Today? 

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

INTS INTENSITY THERAPEUTICS, INC.

Fundamentals

Connect Stocktwits to ChatGPT

Latest INTS News